Taken together, these findings suggest that NF-κB activation (at least through the canonical pathway that activates the RelA/NF-κB1 heterodimer) may actually be blunted in people with schizophrenia compared to people without schizophrenia who have brain inflammation. The gene discussed is NFKB1; the disease is schizophrenia.